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Results: Overall, among SP isolates in AS and EU respec-
tively, S rates were 39.2 and 75.2% for PEN; 45.5 and 82.5%
for CFX; 21.1 and 67.4% for ERY; 19.3 and 75.6% for TET;
37.2 and 74.6% for SXT; and 98.0 and 98.8% for LFX. For all
countries combined the prevalence of MDR SP was 77.4% in
AS and 29.1% in EU. The most prevalent MDR phenotype in
AS was 5-drug R (including PEN, ERY, CFX, TET, and SXT) and
in EU it was 2-drug R (including ERY and TET). Among MDR
isolates, 97.4% in AS and 97.8% in EU were S to LFX. By coun-
try, the MDR rates (%) in EU were as follows: 42.7 FR; 37.9 IT;
37.2 SPN; 26.7 BG; 16.1 GE; and 9.4 UK. Comparatively, the
MDR rates in AS by region were dramatically higher (66.9%
HK, 76.7% SK, 85.6% CH, and 90.6% TW).
Conclusions: Decreased S among many commonly utilized
respiratory agents against SP, in particular beta-lactams and
macrolides, continues to be an issue in both EU and AS. How-
ever, SP remained >98% S to LFX in both regions. MDR rates
among SP is also a concern in AS (77%) and EU (29%), although
rates varied by country. Continued surveillance on a regional
basis is warranted to monitor changes in S among SP and to
help guide local empiric therapy.
doi:10.1016/j.ijid.2008.05.715
44.026
Nationwide Surveillance of in vitro Activities of Tigecy-
cline against Clinical Isolates of Gram-Positive Bacteria in
Taiwan: Broth Microdilution Method vs. the E test
S.M. Tsao1,∗, H.C. Lin2, C.M. Lee3, G.J. Hsu4, C.M. Chen5,
W. Sun6, Y.C. Liu7, T.N. Jang8, Y.J. Cheng9, P.L. Lu10
1 Department of Internal Medicine, Chung Shan Medical Uni-
versity Hospital, Taichung, Taiwan
2 Department of Laboratory Medicine, Taipei Medical Uni-
versity Hospital, Taipei, Taiwan
3 Department of Internal Medicine, Mackay Memorial Hospi-
tal, Taipei, Taiwan
4 Department of Internal Medicine, Chia-Yi Christian Hospi-
tal, Chiayi, Taiwan
5 Department of Internal Medicine, Tungs’ Taichung Metro
Harbor Hospital, Taichung, Taiwan
6 Department of Infection Control, Pao-Chien Hospital, Pin-
tung, Taiwan
7 Department of Internal Medicine, Kaohsiung Veterans Gen-
eral Hospital, Kaohsiung, Taiwan
8 Department of Internal Medicine, Shin Kong Wu Ho-Su
Memorial Hospital, Taipei, Taiwan
9 Department of Internal Medicine, Changhua Christian Hos-
pital, Changhua, Taiwan
10 Department of Internal Medicine, Chung-Ho Memorial
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study, part of TIST-2006
study, aims to compare the in vitro activities of tigecycline
against clinical isolates of Gram-positive bacteria.
Methods: A total of 805 isolates of Gram-positive bacte-
ria were collected from various sources of patients treated
at 20 teaching hospitals. Minimum inhibitory concentrations
(MICs) for tigecycline of these isolates were determined by
the broth microdilution methods according the guidelines
described by Clinical and Laboratory Standards Institute
(CLSI) and the E test as manufacturer’s description. Suscep-
tibility results of tigecycline were interpreted by the MIC
criteria provided by U.S. FDA. Agreement and error analysis
of results generated by two methods were also evaluated.
Results: Susceptibility results of tigecycline are summa-
rized in the table 1. Agreement of two methods was low:
70.8% for MRSA, 26.4% for S. pneumoiae, 20.5% for other
Streptococcus species, and 30.7% for VRE. There was no very
major or major error noted.
Conclusion: Tigecycline exhibited excellent in vitro activ-
ities against gram-positive cocci, including MRSA, VRE,
and penicillin-nonsusceptible S. pneumoiae (PNSSP) isolates
in Taiwan. Correlations between MIC values using broth
microdilution and the E test methods for these organisms
were poor.
doi:10.1016/j.ijid.2008.05.716
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Background: There is evidence that hetero-resistance
may be associated with failure of vancomycin therapy. Most
routine MIC testing methods used in diagnostic laborato-
ries do not detect hVISA strains. There are few published
Canadian studies using other methods for this purpose.
Objective: To use the Macro E-test method and the Gly-
copeptide Resistance Detection (GRD) E-test (AB Biodisk,
Sweden)to assess the prevalence of hVISA among the bac-
teremic isolates of S. aureus at a tertiary care centre in
Canada.
Methods: Ninety two isolates of S. aureus including 7
Methicillin Resistant S. aureus (MRSA) from BSI were tested
by standard, Macro E-test and GRD methods. For the stan-
dard E-test, the organism was tested at 0.5 McFarland on
Mueller Hinton (MH)Agar, and incubated for 24 hours at 35 ◦C.
For Macro E-test, 100l of a 2.0 McFarland suspension was
used on BHI Agar incubated for 48 hours at 35 ◦C. For GRD,
0.5 McFarland inoculum was tested on MH with 5% blood,
incubated for 48 hours at 35 ◦C.A strain was deﬁned as hVISA
if it had an MIC of (>) 8g/ml for vancomycin and teicoplanin
by Macro or GRD E-test.
Results: All the isolates were sensitive to vancomycin
and teicoplanin, when tested by the standard method. The
MIC50 and MIC90 were: vancomycin 1.0g/ml and 1.5g/ml;
teicoplanin 0.5g/ml and 0.75g/ml. Though hVISA was
not detected among the 92 strains tested by Macro E-test
method as per the deﬁned criteria, some strains showed
increased MICs (6.0g/ml). MIC50 and MIC90 were: van-
comycin 3.0g/ml and 6.0g/ml; teicoplanin 3.0g/ml
and 6.0g/ml.The MIC50 and MIC90 by GRD were: van-
comycin 1.0g/ml and 1.5g/ml; teicoplanin 2.0g/ml and
3.0g/ml.
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Conclusions: Routine screening is not warranted as
no hVISA isolates were detected. Some strains had a
Macro E-test MIC of 6.0g/ml for both glycopeptides.
This suggests that periodic screening of S. aureus isolates
from BSI may be useful to check for the occurrence of
hVISA.
doi:10.1016/j.ijid.2008.05.717
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Objectives: S. pneumoniae (SPN) continues to be recog-
nized as a signiﬁcant respiratory and bacteremic pathogen.
Resistance to both oral and parenteral antibiotics used to
treat SPN infection is evolving and newer antibiotics are
needed with anti-SPN activity. This report documents the
activity of tigecycline and comparators against 5501 SPN
collected globally since 2004.
Methods: Between 2004—2007, 387 hospital sites in 48
countries collected 5501 SPN deemed clinically signiﬁcant
from a variety of sources. MICs were determined at each
site using supplied brothmicrodilution panels and MIC results
interpreted by CLSI standards at each site.
Results: The % SPN inhibited at each MIC are shown
below:
Conclusions: Tigecycline demonstrated excellent in vitro
activity against SPN with 100% of isolates inhibited at
≤0.5mcg/ml. Globally, only 61.5% of SPN were suscepti-
ble to penicillin, while 0.2% were resistant to levoﬂoxacin.
Continued surveillance of resistance in SPN to new and
established antimicrobials is warranted.
doi:10.1016/j.ijid.2008.05.718
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Objectives: Tigecycline, a new glycylcycline is an ana-
logue of tetracycline that demonstrates activity against
bacterial strains carrying tetracycline (minocycline) resis-
tance mechanisms. This report documents the activity of TIG
against minocycline resistant isolates collected worldwide,
2004—2007, as part of the Tigecycline Evaluation Surveil-
lance Trial (TEST) study.
Methods: Between 2004 and 2007, 387 hospital sites in
48 countries collected signiﬁcant pathogens associated with
8 specimen types, were identiﬁed to species level and MICs
performed for each strain to a supplied panel of antibiotics
and interpreted according to CLSI guidelines.
Results: The table below illustrates the activity of tige-
cycline to minocycline resistant pathogens.
Conclusions: Tigecycline MIC90s were ≤0.5mcg/ml for
minocycline resistant gram-positive pathogens such as Ente-
rococcus and S. aureus (including MRSA) and ≤8mcg/ml
for minocycline resistant gram-negative pathogens such
as Enterobacteriaceae, including ESBL producers. Tigecy-
cline demonstrated minimal activity against P. aeruginosa.
Tigecycline demonstrates enhanced activity to many
minocycline resistant pathogens.
doi:10.1016/j.ijid.2008.05.719
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Background: Worldwide S. aureus are increasingly dis-
playing resistance to multiple drug classes. Therapeutic
options to multi-drug resistant (MDR) S. aureus phenotypes
are limited. Tigecycline, a new glycylcycline offers the
potential of enhanced activity against MDR S. aureus. The
tigecycline evaluation surveillance trial (T.E.S.T.) evaluated
the activity of tigecycline and comparators to MDR S. aureus
isolated worldwide.
Methods: 335 hospital sites in 47 countries between 2004
and 2007 collected 7,557 clinically signiﬁcant S. aureus.
MICs were determined using broth microdilution panels and
results interpreted as speciﬁed by CLSI at each site. S.
aureus strains were categorized into groups according to the
number of drug classes to which they were resistant (MDR
groups 0 to 4).
Results: MIC90 of tigecycline and comparators for MDR
groups 0 to 4 are shown in the table.
Conclusions: Tigecycline in comparison to 10 relevant
comparators exhibited the lowest MIC90 against S. aureus
isolated worldwide irrespective of MDR phenotype and mul-
tiple drug class resistance.
doi:10.1016/j.ijid.2008.05.720
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Background: Daptomycin is a cyclic lipopeptide with
potent bactericidal activity against Gram-positive organ-
isms. Daptomycin has been used in the USA and Europe for
the treatment of complicated skin and soft tissue (cSSTI)
